HUS and the case for complement

Abstract

Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Excess complement activation underlies atypical HUS and is evident in Shiga toxin-induced HUS (STEC-HUS). This Spotlight focuses on new knowledge of the role of Escherichia coli-derived toxins and polyphosphate in modulating complement andcoagulation, andhowthey affect disease progression and response to treatment.Suchnewinsightsmayimpacton current and future choices of therapies for STEC-HUS.